No Data
No Data
No Data
No Data
No Data
Giant Biogene's Profit Up 47% in 2023
Giant Biogene Holding (HKG:2367) recorded a 47% rise in attributable profit for the year 2023 to 1.45 billion yuan, from 1 billion yuan in 2022, according to the company's annual report posted on the
MT NewswiresApr 30 18:27
巨子生物:二零二三年年報
Futu NewsApr 29 21:36 · Announcements
Giant Biotech (02367.HK): Kefumei's large single product volume continues to focus on medical and aesthetic products approved for catalysis
Incident: The company released its 2023 annual report: 2023 revenue of 3,524 billion yuan (+49.0% YoY), net profit to mother of 1,452 billion yuan (+44.9% YoY), adjusted net profit of 1,469 million yuan
國聯證券Apr 26 07:51
Giant Life (02367.HK): Good Wind takes the lead in recombinant collagen to Qingyun
Collagen: a new favorite in dressings, skincare, medicine and beauty, a blue ocean track with high barriers and high profitability. Question 1. Why are you optimistic about the collagen industry? ——After hyaluronic acid, the gold outlet 1) “Manjin Oil” ingredient has rich application scenarios and is suitable
浙商證券Apr 22 16:46
Giant Biotech (2367.HK) Investment Value Analysis Report: The recombinant collagen market is expected to grow rapidly, and the company's star products achieve word-of-mouth and sales growth
The recombinant collagen market is expected to maintain rapid growth in the future. Compared with animal-derived collagen, recombinant collagen has higher biological activity and biocompatibility, lower immunogenicity, lower risk of hidden hazards of missed pathogens, greater water solubility, and less fine
華通證券國際Apr 18 00:00
A quick overview of the Hong Kong market | The three major indices closed up slightly, and the Hang Seng Index stopped falling for 4 consecutive years
Semiconductor stocks strengthened, with Shanghai Fudan up more than 8%; heavy infrastructure stocks rose, with China Metallurgical, China Railway, and China Communications Construction up about 3%.
Futu NewsApr 17 16:24
No Data
No Data